128 related articles for article (PubMed ID: 7748459)
1. DNA sequence preferences at sites cleaved by human DNA topoisomerase II in response to novel quinolone derivatives.
Huff AC; Robinson RG; Evans AC; Selander KN; Wentland MP; Rake JB; Coughlin SA
Anticancer Drug Des; 1995 Apr; 10(3):251-76. PubMed ID: 7748459
[TBL] [Abstract][Full Text] [Related]
2. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
3. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility.
Borgnetto ME; Zunino F; Tinelli S; Kas E; Capranico G
Cancer Res; 1996 Apr; 56(8):1855-62. PubMed ID: 8620504
[TBL] [Abstract][Full Text] [Related]
4. Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.
Bigioni M; Zunino F; Tinelli S; Austin CA; Willmore E; Capranico G
Biochemistry; 1996 Jan; 35(1):153-9. PubMed ID: 8555169
[TBL] [Abstract][Full Text] [Related]
5. Application of a degenerate consensus sequence to quantify recognition sites by vertebrate DNA topoisomerase II.
Spitzner JR; Muller MT
J Mol Recognit; 1989 Sep; 2(2):63-74. PubMed ID: 2561527
[TBL] [Abstract][Full Text] [Related]
6. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Pommier Y; Orr A; Kohn KW; Riou JF
Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259
[TBL] [Abstract][Full Text] [Related]
8. Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.
Bromberg KD; Burgin AB; Osheroff N
Biochemistry; 2003 Apr; 42(12):3393-8. PubMed ID: 12653542
[TBL] [Abstract][Full Text] [Related]
9. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.
Pommier Y; Capranico G; Orr A; Kohn KW
Nucleic Acids Res; 1991 Nov; 19(21):5973-80. PubMed ID: 1658748
[TBL] [Abstract][Full Text] [Related]
10. Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro.
Han YH; Austin MJ; Pommier Y; Povirk LF
J Mol Biol; 1993 Jan; 229(1):52-66. PubMed ID: 8380617
[TBL] [Abstract][Full Text] [Related]
11. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT
Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone.
Freudenreich CH; Chang C; Kreuzer KN
Cancer Res; 1998 Mar; 58(6):1260-7. PubMed ID: 9515814
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II-mediated DNA cleavage: evidence for distinct regions of enzyme-DNA contacts.
Alsner J; Sorensen HV; Schmidt VK; Sorensen BS; Westergaard O
J Mol Biol; 1996 Jun; 259(3):317-24. PubMed ID: 8676370
[TBL] [Abstract][Full Text] [Related]
14. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
[TBL] [Abstract][Full Text] [Related]
15. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II.
Capranico G; De Isabella P; Tinelli S; Bigioni M; Zunino F
Biochemistry; 1993 Mar; 32(12):3038-46. PubMed ID: 8384486
[TBL] [Abstract][Full Text] [Related]
16. Streptonigrin-induced topoisomerase II sites exhibit base preferences in the middle of the enzyme stagger.
Leteurtre F; Kohlhagen G; Pommier Y
Biochem Biophys Res Commun; 1994 Sep; 203(2):1259-67. PubMed ID: 8093042
[TBL] [Abstract][Full Text] [Related]
17. Enhanced amsacrine-induced mutagenesis in plateau-phase Chinese hamster ovary cells, with targeting of +1 frameshifts to free 3' ends of topoisomerase II cleavable complexes.
Patteson K; Wang P; Povirk LF
Cancer Res; 1999 Aug; 59(15):3682-8. PubMed ID: 10446982
[TBL] [Abstract][Full Text] [Related]
18. Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons.
Borgnetto ME; Tinelli S; Carminati L; Capranico G
J Mol Biol; 1999 Jan; 285(2):545-54. PubMed ID: 9878428
[TBL] [Abstract][Full Text] [Related]
19. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
Hammonds TR; Foster SR; Maxwell A
J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
